JGC
ESPR

J. Goldman & Co’s Esperion Therapeutics ESPR Stock Holding History

J. Goldman & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-202,500
Closed -$1.26M – 391
2022
Q4 		$1.26M Buy
+202,500
New +$1.45M 0.06% 207
2020
Q1 		– Sell
-90,000
Closed -$5.37M – 273
2019
Q4 		$5.37M Buy
+90,000
New +$4.05M 0.38% 73
2018
Q3 		– Sell
-84,500
Closed -$3.31M – 292
2018
Q2 		$3.31M Buy
+84,500
New +$4.27M 0.17% 167
2018
Q1 		– Sell
-26,000
Closed -$1.71M – 368
2017
Q4 		$1.71M Sell
26,000
-5,000
-16% -$269K 0.09% 201
2017
Q3 		$1.55M Sell
31,000
-66,500
-68% -$3.21M 0.08% 212
2017
Q2 		$4.51M Buy
+97,500
New +$3.59M 0.24% 115

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

J. Goldman & Co's ESPR Position: Q1 2023 in Review

J. Goldman & Co sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 293,864 shares — an estimated $1.83M sold.

J. Goldman & Co first reported a position in ESPR in Q4 2016 and held it in 14 quarters. The position peaked at $3.71M in Q1 2018. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • J. Goldman & Co reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • J. Goldman & Co sold 293,864 Esperion Therapeutics shares in Q1 2023, an estimated $1.83M.
  • J. Goldman & Co first reported a position in Esperion Therapeutics in Q4 2016 and held it in 14 quarters.
  • J. Goldman & Co's Esperion Therapeutics position peaked at $3.71M in Q1 2018.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on J. Goldman & Co's 13F filing for Q1 2023, filed 15 May 2023.